Kailera Therapeutics, Inc.
KLRANasdaq
$18.55
↑ +1.3%Jul 17 close · end-of-day
Price
1Y↓ -28.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Our principal executive offices are located in Waltham, Massachusetts.
- CEO
- Ronald C. Renaud, Jr.
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 145
- Headquarters
- Massachusetts
- Website
- www.kailera.com
Earnings
KLRA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$3,650.00↓ -79.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
No annual data.
| Line item | Q1 '25 | Q1 '26 |
|---|---|---|
| Revenue | — | — |
| Gross profit | — | — |
| Operating income | -$20.5M | -$84.7M |
| Net income | -$18.0M | -$78.9M |
| Diluted EPS | -$17,983.00 | -$3,650.00 |
| Operating cash flow | -$18.2M | -$68.3M |
| Free cash flow | — | — |
| Gross margin | — | — |
| Operating margin | — | — |
| Net margin | — | — |
Company news
Jul 10, 2026
Jul 7, 2026
- 13d agoEli Lilly's Market Cap Balloons Again On This IPO's Setbackfinance.yahoo.com
- 13d agoUpdate: Kailera Says Oral Small Molecule KAI-7535 Achieves Up to 11% Weight Loss in Phase 3 Trial; Shares Fallfinance.yahoo.com
- 13d agoKailera Says Oral Small Molecule KAI-7535 Achieves Up to 11% Weight Loss in Phase 3 Trialfinance.yahoo.com
- 13d agoKailera says obesity pill succeeds in late-stage trial in Chinabiopharmadive.com
- 13d agoKailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535finance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-09 | Renaud Ronald C JR· CEO & President | Option exercise | 38,094 | $5.25 | $199,993.50 | filing |
| 2026-04-20 | Kaplan Andrew T. | Buy | 8,398,438 | $16.00 | $134.4M | filing |
| 2026-04-20 | BAIN CAPITAL INVESTORS LLC | Buy | 8,398,438 | $16.00 | $134.4M | filing |
| 2026-04-20 | Koppel Adam | Buy | 1,562,500 | $16.00 | $25.0M | filing |
| 2026-04-20 | Bain Capital Life Sciences Investors, LLC | Buy | 1,562,500 | $16.00 | $25.0M | filing |
| 2026-04-20 | RTW INVESTMENTS, LLC | Buy | 500,000 | $16.00 | $8.0M | filing |
| 2026-04-20 | RTW INVESTMENTS, LLC | C | 10,276,820 | — | — | filing |
| 2026-04-20 | Koppel Adam | C | 16,875,000 | — | — | filing |
| 2026-04-20 | Koppel Adam | C | 4,145,768 | — | — | filing |
| 2026-04-20 | BAIN CAPITAL INVESTORS LLC | C | 17,857,143 | — | — | filing |
| 2026-04-20 | Bain Capital Life Sciences Investors, LLC | C | 16,875,000 | — | — | filing |
| 2026-04-20 | Bain Capital Life Sciences Investors, LLC | C | 4,145,768 | — | — | filing |
| 2026-04-20 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | C | 2,034,133 | — | — | filing |
| 2026-04-20 | Kaplan Andrew T. | C | 17,857,143 | — | — | filing |
| 2026-04-20 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | C | 9,477,719 | — | — | filing |
Latest 15 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.